Loading...
ANVS logo

Annovis Bio, Inc.NYSE:ANVS Rapport sur les actions

Capitalisation boursière US$84.7m
Prix de l'action
US$1.89
US$12.5
84.9% sous-évalué décote intrinsèque
1Y-41.1%
7D-1.6%
1D
Valeur du portefeuille
​
Voir

Annovis Bio, Inc.

NYSE:ANVS Rapport sur les actions

Capitalisation boursière : US$84.7m

Annovis Bio (ANVS) Aperçu de l'action

Annovis Bio, Inc. est une société qui développe des médicaments pour le traitement de la neurodégénérescence aux États-Unis. Plus de détails

ANVS analyse fondamentale
Score flocon de neige
Évaluation3/6
Croissance future0/6
Performances passées0/6
Santé financière6/6
Dividendes0/6

Récompenses

Se négocie à 99.8% en dessous de notre estimation de sa juste valeur

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Réalise moins d'un million de dollars de revenus ( $0 )

Volatilité du cours de l'action au cours des 3 derniers mois par rapport au marché US

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

+ 1 plus de risques

ANVS Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Annovis Bio, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Annovis Bio
Historique des cours de bourse
Prix actuel de l'actionUS$1.89
Plus haut sur 52 semainesUS$5.50
Plus bas sur 52 semainesUS$1.54
Bêta1.19
Variation sur 1 mois-21.25%
Variation sur 3 mois-24.10%
Variation sur 1 an-41.12%
Variation sur 3 ans-86.10%
Variation sur 5 ans-97.92%
Évolution depuis l'introduction en bourse-80.29%

Nouvelles et mises à jour récentes

Article d’analyse • May 22

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.

Recent updates

Article d’analyse • May 22

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Article d’analyse • Jun 25

We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Article d’analyse • Dec 06

We're A Little Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Oct 17

Annovis Bio To Continue Alzheimer's Disease Clinical Trials

Summary In April 2024, Annovis Bio's lead drug, Buntanetap, failed to show efficacy in its phase 2/3 Alzheimer's Disease trial, leading to a 70% stock drop. The company plans to proceed with a phase 3 trial despite the lack of convincing efficacy data and significant financial constraints. Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 27

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Summary Annovis Bio's Buntanetap shows promising results in treating Alzheimer's and Parkinson's, with significant cognitive and motor function improvements in Phase 2/3 and Phase 3 trials. The drug also improved motor function in Phase 3 Parkinson’s trials, especially in advanced cases and PIGD patients. Buntanetap's mechanism of action targets neurotoxic proteins, offering symptomatic and possibly disease-modifying benefits, making it a valuable IP for combination therapies. Buntanetap showed statistically significant cognitive improvement in Phase 2/3 Alzheimer’s trials, particularly at 15mg and 30mg doses. Unfortunately, its short cash runway can't be ignored. So, I maintain a "hold" rating on ANVS until it secures more long-term financing. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Summary Analysis of Annovis Bio's lead product, buntanetap, tested in neurodegenerative diseases suggests questionable efficacy, in our opinion. Recent topline data from the PD phase 3 study shows no efficacy in the ITT population among positive post-hoc claims. The company intends to meet with the FDA and discuss an NDA filing, which, we believe, is currently not supported by the available evidence. Financial constraints persist, with ~$4M cash left on the balance sheet. Read the full article on Seeking Alpha
Seeking Alpha • Jun 30

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Summary Annovis Bio's only potential catalyst is the upcoming Phase 3 readout for Parkinson's disease. The company's changes to the primary endpoints of that trial, contrary to the FDA's wishes, cause concern. There is now more certainty that the Phase 2/3 trial in Alzheimer's disease failed to reach its primary endpoints. A recent CFO resignation, lack of funding and the company's wishes to conduct large further trials lead to a Strong Sell rating. Read the full article on Seeking Alpha
Seeking Alpha • May 02

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

Summary Annovis reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and the focus on mild AD patients were not pre-specified, raising concerns. Annovis faces financial challenges and may see a significant decline in stock prices. Read the full article on Seeking Alpha
Seeking Alpha • Feb 12

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s symptoms, which could suggest that a majority of patients in the higher 20 mg (higher dose) cohort experienced an improvement. A positive topline readout for the buntanetap 20mg dose would have a positive readthrough to the Alzheimer’s results due in 2Q24. The company has the overhang of needing to raise cash imminently and faces general market skepticism. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Annovis And Alzheimer's Disease: The Best-Laid Plans

Summary Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The primary triggers for Alzheimer's disease are unrelated to amyloid, making it unlikely that Annovis' buntanetap will substantially impact disease progression. Anti-amyloid drugs only slow down the progression of Alzheimer's disease in its early stages in APOE4 carriers and may not be effective in the long-term. Read the full article on Seeking Alpha
Seeking Alpha • Jan 20

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Summary Annovis Bio has two upcoming major catalysts, a phase 2/3 AD clinical trial and a phase 3 PD clinical trial. The investigational drug, Buntanetap, is an enantiomer of a molecule previously tested for AD, with no success. We believe that the likelihood of success for Buntanetap in clinical trials is low, and if the drug fails, Annovis Bio's stock could plummet to or below its cash reserves. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Summary Annovis is expected to report data from Phase 3 and Phase 2/3 trials in Parkinson's and Alzheimer's disease, respectively. The efficacy of Annovis' lead compound, Buntanetap, is difficult to align with its proposed disease-modifying mechanism of action. Annovis has a low market cap and may need to raise capital around the upcoming topline data. Given previously seen stock volatility, I believe a good understanding of the upcoming reporting is in place. Read the full article on Seeking Alpha
Article d’analyse • Sep 08

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 28

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Summary Results from the phase 3 study, using buntanetap for the treatment of patients with Parkinson's Disease, are expected to be released before the end of 2023. The global Parkinson's Disease drug market is expected to reach $10.4 billion by 2031. Buntanetap is also being explored in an ongoing phase 2/3 study for the treatment of patients with mild to moderate Alzheimer's Disease. Annovis Bio had $16.8 million in cash as of March 31, 2023; enough cash to fund its operations into Q1 of 2024 and will likely need to raise additional cash before end of 2023. Read the full article on Seeking Alpha
Seeking Alpha • Feb 08

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Annovis Bio (NYSE:ANVS) announced Wednesday the EU approval to bring additional 48 trial sites for its Phase 3 study for lead candidate buntanetap in the treatment of Parkinson's disease ("PD"). With 50 clinical trial sites open in the U.S., the clinical-stage biotech is currently enrolling patients for the randomized study, which tests buntanetap 10mg or 20mg vs. placebo in addition to standard of care for six months. "We are pleased to significantly expand our geographic reach with the addition of these EU sites that gives us the ability to efficiently enroll European patients in our study," Chief Executive of Annovis (ANVS) Maria Maccecchini remarked. The company intends to enroll early PD patients in these additional trial sites, spread across countries such as Italy, Spain, Hungary, Poland, and Germany. An interim readout is expected in Q2 2023 if there is a sufficient number of patients who have received two months of therapy. Seeking Alpha contributor Terry Chrisomalis issued a Strong Buy rating on Annovis (ANVS) last year, citing the potential of buntanetap in PD.
Article d’analyse • Jan 28

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 25

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Clinical stage biotech Annovis Bio (NYSE:ANVS) traded higher in the morning hours Wednesday after the company highlighted "strong" patient enrollment in its Phase 3 trial for Parkinson's disease (PD) candidate buntanetap. "We are very pleased with the pace of enrollment in our Phase 3 study, designed to assess the safety and efficacy of buntanetap in early-stage Parkinson's patients," Chief Executive Maria Maccecchini noted. The company has arranged an interim data analysis in Q2 2023 to see if its original target of 150 patients per arm will be enough to demonstrate a treatment effect. "Based on the current enrollment, the Company anticipates having a sufficient number of patients who have received two months of therapy to conduct an interim analysis in the second quarter of 2023," Annovis (ANVS) added. Buntanetap, formerly known as ANVS401 or Posiphen, has potential not only in PD but also in Alzheimer's, Seeking Alpha contributor Terry Chrisomalis points out.
Seeking Alpha • Oct 06

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Summary Green light received from the FDA to initiate a phase 3 study using buntanetap for the treatment of early-stage Parkinson's Disease patients. The global Parkinson's Disease market is expected to reach $8.38 billion by end of 2026. Potential to receive clearance to initiate a phase 3 study using buntanetap for the treatment of patients with Alzheimer's Disease if end of phase 2 meeting goes well. Other drugs in the pipeline include ANVS301 for advanced Alzheimer's Disease/dementia and ANVS405 for traumatic brain injury and stroke.

Rendement pour les actionnaires

ANVSUS BiotechsUS Marché
7D-1.6%-3.1%-2.9%
1Y-41.1%26.9%23.5%

Rendement vs Industrie: ANVS a sous-performé le secteur US Biotechs qui a rapporté 26.9 % au cours de l'année écoulée.

Rendement vs marché: ANVS a sous-performé le marché US qui a rapporté 23.5 % au cours de l'année écoulée.

Volatilité des prix

Is ANVS's price volatile compared to industry and market?
ANVS volatility
ANVS Average Weekly Movement14.0%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Cours de l'action stable: Le cours de l'action de ANVS a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de ANVS ( 14% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

FondéeSalariésPDGSite web
20087Maria Maccecchiniwww.annovisbio.com

Annovis Bio, Inc. est une société qui développe des médicaments pour le traitement de la neurodégénérescence aux États-Unis. Le principal produit candidat de la société est le Buntanetap, qui est en phase 3 pour le traitement de la maladie d'Alzheimer, ainsi qu'en phase 3 ouverte pour le traitement de la maladie de Parkinson. La société développe également ANVS405, qui fait l'objet d'essais cliniques de phase 2 et 3 pour le traitement des lésions cérébrales traumatiques et/ou des accidents vasculaires cérébraux, et ANVS301, dont l'essai clinique de phase 1 est terminé et qui a été développé pour augmenter les capacités cognitives aux stades avancés de la maladie d'Alzheimer et de la démence.

Annovis Bio, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Annovis Bio se comparent-ils à sa capitalisation boursière ?
ANVS statistiques fondamentales
Capitalisation boursièreUS$84.66m
Bénéfices(TTM)-US$28.85m
Recettes(TTM)n/a
0.0x
Ratio P/S
-2.8x
Ratio P/E

Le site ANVS est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ANVS compte de résultat (TTM)
RecettesUS$0
Coût des recettesUS$0
Marge bruteUS$0
Autres dépensesUS$28.85m
Les revenus-US$28.85m

Derniers bénéfices déclarés

Dec 31, 2025

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-0.68
Marge brute0.00%
Marge bénéficiaire nette0.00%
Ratio dettes/capitaux propres0%

Quelles ont été les performances à long terme de ANVS?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/05 10:26
Cours de l'action en fin de journée2026/06/05 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Annovis Bio, Inc. est couverte par 3 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Jason KolbertD. Boral Capital LLC.
Jason McCarthyMaxim Group